A Practice-based Evaluation of a Novel Resin Luting Material and Dentine Bonding Agent

Dental Update ◽  
2021 ◽  
Vol 48 (1) ◽  
pp. 34-40
Author(s):  
Peter Sands ◽  
Russell J Crisp ◽  
Owen Thompson ◽  
FJ Trevor Burke
Keyword(s):  
Delivery System ◽  
Research Group ◽  
Clinical Relevance ◽  
Ease Of Use ◽  
Bonding Agent ◽  
The Novel ◽  
Practice Based Research ◽  
Luting Material ◽  
Clinical Cases

This study evaluated the handling of a recently introduced resin luting material and its associated universal bonding agent by a group of practice-based researchers. Eleven evaluators from the practice-based research group, the PREP Panel, were sent explanatory letters and a pack of the materials under investigation, with a request to use them, where indicated, for 10 weeks and then to complete a questionnaire designed to elicit the evaluators' views on the handling of the materials. In total, 217 restorations were placed: the results from the questionnaire indicated strong acceptance of the ease of use of the materials. The novel cement delivery system was found to reduce waste, the cement was of ideal viscosity, and the design of the mixing tips and easier clean up were particularly noteworthy. The investigators also appreciated that the same cement can cover adhesive and self-adhesive indications. Some clinical cases of different indications were documented and selected illustrations are presented. CPD/Clinical Relevance: The luting system which was evaluated was found to be easy to use, with reduced waste of material.

The Effect of Three Variables on Shear Bond Strength When Luting A Resin Inlay to Dentin

10.2341/08-82 ◽  
2009 ◽  
Vol 34 (3) ◽  
pp. 288-292 ◽  
Author(s):  
J-I. Lee ◽  
S-H. Park
Keyword(s):  
Bond Strength ◽  
Clinical Relevance ◽  
Shear Bond Strength ◽  
Bonding Agent ◽  
Dentin Surface ◽  
Luting Material

Clinical Relevance In order to maximize the bond strength of a resin inlay to dentin, the exposed dentin surface should be sealed with DBA before taking an impression. In addition, the bonding agent should be gently air dried and light cured before applying the luting material.

Self Microemulsifying Nutraceutical and Drug Delivery Systems

2014 ◽  
Vol 7 (3) ◽  
pp. 2520-2528 ◽  
Author(s):  
Vikrant P Wankhade ◽  
Nivedita S Kale ◽  
K.K Tapar
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Ternary Phase Diagram ◽  
Aqueous Solubility ◽  
Oral Formulation ◽  
Water Soluble ◽  
Drug Dissolution ◽  
The Novel ◽  
Peristaltic Movement

Many chemical entities and nutraceuticals are poor water soluble and show high lipophilicity. It’s difficult to formulate them into oral formulation because of its low aqueous solubility which ultimately affects bioavailability. To enhance the bioavailability of such drugs compounds, self microemulsifying drug delivery system is the reliable drug delivery system. In this system the drug is incorporated in the isotropic system and formulated as unit dosage form. Self microemulsifying drug delivery system is the novel emulsified system composed of anhydrous isotropic mixture of oils, surfactant, and co solvent and sometimes co surfactant. Drug is directly dispersed into the entire gastro intestinal tract with continuous peristaltic movement and drug is available in the solution form of microemulsion, absorbed through lymphatic system and bypasses the dissolution step. Hence they increase the patient compliance. The excipients are selected on basis of construction of ternary phase diagram. Self micro-emulsifying drug delivery system is very useful for drug in which drug dissolution is rate limiting step. This review describes the novel approaches and evaluation parameters of the self microemulsifying drug delivery system towards different classic drugs, proteins-peptides, and nutraceuticals in various oral microemulsion compositions and microstructures.

Short Review on Novel Dosage Form

2021 ◽  
pp. 301-303
Author(s):  
Tushar N. Sonawane ◽  
Pradip D. Dhangar ◽  
Sagar D Patil ◽  
Azam Z. Shaikh
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Drug Delivery Systems ◽  
Drug Effects ◽  
Short Review ◽  
Delivery Systems ◽  
The Novel ◽  
Novel Drug Delivery System ◽  
Novel Drug

Novel Drug Delivery Systems are one of the widely use delivery system in the presence scenario. Novel drug delivery system is a novel approach to drug delivery that addresses the limitations of the traditional drug delivery systems. In the form of a Novel Drug Delivery System an existing drug molecule can get a new life. The novel drug delivery system is Increases bioavailability and it Can be used for long-term treatments of chronic illness, Sustained maintenance of plasma drug levels as well as it Decreased adverse drug effects in the total amount of drugs required thus reducing side effects it Improved patient compliance due to reduction in number and frequency of doses required. There is less damage sustained by normal tissue due to targeted drug delivery. In this paper our main focus to give the throughout knowledge of some newer (Novel drug delivery system) to understand the concept of the Novel dossage form.

Orthodontic Conundrums Part 2: Finishing Cases to a Class III Molar Relationship

2021 ◽  
Vol 14 (1) ◽  
pp. 27-31
Author(s):  
Naeem I Adam ◽  
Adam Jowett ◽  
Trevor Hodge
Keyword(s):  
Clinical Relevance ◽  
Orthodontic Treatment ◽  
Class I ◽  
Patient Harm ◽  
Class Iii ◽  
Facial Profile ◽  
Clinical Cases

This is the second article in a series on conundrums in orthodontics. A Class I molar relationship is a frequent aim of orthodontic treatment. There are, however, examples where intentionally finishing to a Class III molar relationship is the more pragmatic and preferable option. Pursuing this approach in the appropriate circumstances may, for example, prevent deleterious consequences to the facial profile or avoid the need for further dental extractions. This article explores the indications for finishing cases to a Class III molar relationship with illustrated clinical cases. CPD/Clinical Relevance: Dogmatic attempts to deliver Class I molar relationships, in all cases, without consideration of the consequences, have the potential to cause the patient harm. The orthodontist must then consider all possible options available, including those resulting in a Class III molar relationship.

Contact Tracing Applications Against COVID-19: A Systematic Review (Preprint)

2021 ◽  
Author(s):  
Ahmad Nabeel ◽  
Salman AlSabah ◽  
Eliana Al Haddad ◽  
Hutan Ashrafian
Keyword(s):  
Systematic Review ◽  
Critical Mass ◽  
Population Level ◽  
Ease Of Use ◽  
Contact Tracing ◽  
The Novel ◽  
Scientific Databases ◽  
Manual Methods ◽  
Novel Coronavirus ◽  
Transmission Of Disease

BACKGROUND The novel coronavirus 2019 (COVID-19) pandemic has triggered public anxiety around the world. So far, the evidence suggests that prevention on a public scale is the most effective health measure for thwarting the progress of COVID-19. Another critical aspect of preventing COVID-19 is contact tracing. OBJECTIVE We aimed to investigate the effectiveness of contact tracing applications currently available in the context of the COVID-19 pandemic. METHODS We undertook a systematic review and narrative synthesis of all literature relating to contact tracing applications in the context of COVID-19. We searched 3 major scientific databases. Only articles that were published in English and were available as full-text articles were selected for review. Data were extracted and narrative syntheses conducted. RESULTS Five studies relating to COVID-19 were included in the review. Our results suggest that digitalized contact tracing methods can be beneficial for impeding the progress of COVID-19. Three key themes were generated from this systematic review. First, the critical mass of application adoption must be attained at the population level before the sensitivity and positive predictive value of the solution can be increased. Second, usability factors such as access, ease of use and the elimination of barriers are essential in driving this uptake. Third, privacy must be ensured where possible as it is the single most significant barrier against achieving critical mass. CONCLUSIONS The COVID-19 pandemic has claimed more than 2 million lives globally, with over 100 million confirmed cases. Contact tracing can rapidly identify potentially infected individuals before the emergence of severe or critical symptoms, and it can also prevent the subsequent transmission of disease from secondary cases when implemented efficiently. Contact tracing methods have proved to be beneficial for impeding the progress of COVID-19 as compared to older, more labor intensive manual methods.

Clinical cases of eculizumab use as a part of complex therapy in patients with severe COVID-19.

2021 ◽  
Author(s):  
Р.А. Майер ◽  
Б.А. Бакиров ◽  
А.А. Набиева ◽  
Д.А. Кудлай
Keyword(s):  
Virus Disease ◽  
Membrane Attack Complex ◽  
Lung Ventilation ◽  
Blood Analysis ◽  
The Novel ◽  
Reactive Protein ◽  
Corona Virus ◽  
Complex Therapy ◽  
Novel Coronavirus ◽  
Clinical Cases

Введение. В последние 2 года серьезной проблемой для всего мирового сообщества стало распространение новой коронавирусной (CoV) инфекции COVID-19 (COrona VIrus Disease-2019). Ввиду сложившихся событий в лечении COVID-19 активно стали применяться новые молекулы и уже зарегистрированные лекарственные препараты, доказавшие свою эффективность при других заболеваниях. Цель исследования: оценить эффективность применения препарата экулизумаб у пациентов с тяжелой формой течения COVID-19. Материалы и методы. Проанализированы 3 клинических случая применения препарата экулизумаб в составе комплексной терапии у пациентов с тяжелой формой течения COVID-19. Для оценки эффективности лечения проводился мониторинг основных клинико-лабораторных показателей, а также показателей, характеризующих воспалительный процесс при коронавирусной инфекции: общий анализ крови, биохимический анализ крови, проанализированы уровни таких показателей как ферритин, С-реактивный белок, интерлейкин-6, лактатдегидрогеназа и мембраноатакующий комплекс. Результаты. На фоне проводимой терапии выявлено снижение концентрации основных маркеров воспаления относительно исходных значений. Заключение. Комплексная терапия, включающая экулизумаб, облегчает течение заболевания, позволяет сократить длительность пребывания пациентов в отделении реанимации и интенсивной терапии, укорачивает срок их пребывания на искусственной вентиляции легких, тем самым снижая процент летальности. Background. In the past two years, the incidence of the novel coronavirus (CoV) infection COVID-19 (COrona Virus Disease-2019) has been a serious problem for the global community. Considering these circumstances, new molecules and already registered drugs that have proven their effectiveness in other diseases, began to be actively used in COVID-19 treatment. Objectives: to assess the effi cacy of eculizumab in patients with severe COVID-19. Patients/Methods. Three clinical cases of eculizumab use as a part of complex therapy in patients with severe COVID-19 have been analyzed. To assess the treatment efficacy, the main clinical and laboratory parameters and indicators of inflammatory process in coronavirus infection were monitored (clinical blood analysis, biochemical blood test, levels of ferritin, C-reactive protein, interleukin-6, lactate dehydrogenase and membrane attack complex). Results. Under the therapy we found the reduction of concentration of the main inflammation markers relative to the initial values. Conclusions. Complex therapy with eculizumab facilitates the course of the disease, reduces the stay duration of patients in the intensive care unit, shortens the period of artificial lung ventilation, thereby reducing the mortality rate.

Practice-Based Research: Opportunities and Obstacles

PEDIATRICS ◽  
1988 ◽  
Vol 82 (3) ◽  
pp. 399-406
Author(s):  
K. K. Christoffel ◽  
H. J. Binns ◽  
J. A. Stockman ◽  
P. McGuire ◽  
J. Poncher ◽  
...  
Keyword(s):  
Research Group ◽  
Critical Role ◽  
Practice Research ◽  
Pediatric Practice ◽  
Patient Registries ◽  
Services Research ◽  
Hospital Perspective ◽  
Study Protocols ◽  
Practice Based Research ◽  
Research Consortium

Renewed interest in practice-based research reflects growing realization of the limitations of research from a hospital perspective. Practice-based pediatric research promises to broaden the range and severity of conditions commonly studied, to enhance the study of the natural history of disease and of normal development, to provide normal controls and standards, and to facilitate recruitment of adequate sample sizes. Cohort, incidence, and health services research will be promoted by the development of patient registries. The Chicago area Pediatric Practice Research Group is a research consortium of 81 practitioners in 27 office practices. Formed in 1984, it receives logistic and financial support from children's Memorial Hospital, with which it is affiliated. The Pediatric Practice Research Group has undertaken six studies, most with outside funding. During these studies, some unifying characteristics of practice-based research have emerged. These include the need to tailor study protocols to individual practice characteristics and routines and the critical role of office staff in the conduct of research. Features can be identified that make specific studies more or less intrusive into office functioning. It has proved feasible to obtain data of high quality and reproducibility despite geographically scattered data collection sites. This review of Pediatric Practice Research Group activities and experience is intended to open an exchange of ideas with others interested in practice-based research.

Sign in / Sign up

Export Citation Format

Share Document